RMD ResMed Inc.

ResMed to Report Third Quarter Fiscal 2024 Earnings on April 25, 2024

ResMed to Report Third Quarter Fiscal 2024 Earnings on April 25, 2024

SAN DIEGO, April 04, 2024 (GLOBE NEWSWIRE) -- ResMed (NYSE: RMD, ASX: RMD) today announced it plans to release financial and operational results for the third quarter of fiscal year 2024 on Thursday, April 25, 2024, after the New York Stock Exchange closes. Following the release, ResMed management will host a webcast to discuss the results. Other forward-looking and material information may also be discussed during the webcast.

Earnings webcast details:

 • Location:
 • Date:Thursday, April 25, 2024
 • Time:1:30 p.m. PDT / 4:30 p.m. EDT
 • International:London, Thursday, April 25, 2024, 9:30 p.m. BST

Sydney, Friday, April 26, 2024, 6:30 a.m. AEST

   

Please note, ResMed does not use outside phone lines to access the earnings call, the call is accessible via the above webcast link only.

A replay of the earnings webcast will be accessible on ResMed’s website and available approximately two hours after the webcast. In addition, a phone replay will be available approximately three hours after the webcast and will be accessible from April 25, 2024, until May 9, 2024, at:

  • U.S.: +1 877.660.6853
  • International: +1 201.612.7415
  • Conference ID: 13745785

About ResMed

At ResMed (NYSE: RMD, ASX: RMD) we pioneer innovative solutions that treat and keep people out of the hospital, empowering them to live healthier, higher-quality lives. Our digital health technologies and cloud-connected medical devices transform care for people with sleep apnea, COPD, and other chronic diseases. Our comprehensive out-of-hospital software platforms support the professionals and caregivers who help people stay healthy in the home or care setting of their choice. By enabling better care, we improve quality of life, reduce the impact of chronic disease, and lower costs for consumers and healthcare systems in more than 140 countries. To learn more, visit and follow @ResMed.

For investors

+1 858.836.5000 

For media

+1 619.510.1281





EN
04/04/2024

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on ResMed Inc.

 PRESS RELEASE

Resmed Announces Participation in the Bank of America Global Healthcar...

Resmed Announces Participation in the Bank of America Global Healthcare Conference 2025 SAN DIEGO, Sept. 16, 2025 (GLOBE NEWSWIRE) -- Resmed (NYSE: RMD, ASX: RMD) today announced Mick Farrell, chairman and chief executive officer, and Dr. Carlos Nunez, chief medical officer, will present at the Bank of America Global Healthcare Conference 2025 on Tuesday, September 23, 2025, beginning at approximately 1:20 p.m. (British Summer Time) in London. More information about this event, including access to the live, audio-only webcast, may be accessed by visiting . The audio-only webcast replay w...

 PRESS RELEASE

Resmed Launches Sleep Institute to Elevate Sleep Health as a Global Pr...

Resmed Launches Sleep Institute to Elevate Sleep Health as a Global Priority New global clinical insights initiative debuts at World Sleep Congress 2025 to help drive innovation in sleep health care SAN DIEGO, Sept. 03, 2025 (GLOBE NEWSWIRE) -- Resmed (NYSE: RMD, ASX: RMD), the leading health technology company focused on sleep, breathing, and care delivered in the home, today announced the launch of , a global clinical insights initiative dedicated to advancing the science and understanding of sleep health. Sleep Institute partners with clinicians, researchers, policymakers, and healt...

 PRESS RELEASE

Obstructive Sleep Apnea Expected to Affect Nearly 77 million U.S. Adul...

Obstructive Sleep Apnea Expected to Affect Nearly 77 million U.S. Adults by 2050, New Resmed Study Finds Published in The Lancet Respiratory Medicine, research reveals sharp rise in OSA, especially among women, highlighting the need for earlier diagnosis, preventative strategies, and personalized care SAN DIEGO, Aug. 27, 2025 (GLOBE NEWSWIRE) -- Resmed (NYSE: RMD, ASX: RMD), the leading health technology company focused on sleep, breathing, and care delivered in the home, today announced the publication of a landmark study in projecting a significant rise in obstructive sleep apnea (OS...

 PRESS RELEASE

Resmed Strengthens Innovation Leadership with Dual Red Dot Design Awar...

Resmed Strengthens Innovation Leadership with Dual Red Dot Design Awards and 10,000 Patents and Designs Milestones underscore Resmed’s leadership and commitment to delivering life-changing health technology that people love SAN DIEGO, Aug. 21, 2025 (GLOBE NEWSWIRE) -- Resmed (NYSE: RMD, ASX: RMD), the leading health technology company focused on sleep, breathing, and care delivered in the home, today announced that its  nasal cradle mask won two prestigious : Product Design 2025 in both the Innovative Products and Medical Design & Healthcare categories. The AirTouch N30i features Resmed...

 PRESS RELEASE

Resmed Announces Election of Nicole Mowad-Nassar to Board of Directors...

Resmed Announces Election of Nicole Mowad-Nassar to Board of Directors and Upcoming Retirement of Rich Sulpizio Mowad-Nassar is Senior Vice President at AbbVie and President, Specialty and U.S. Therapeutics Operations Her appointment brings over 30 years of strategic, commercial, and operational expertise in the pharmaceutical and broader healthcare industry, with a focus on digital innovation SAN DIEGO, Aug. 18, 2025 (GLOBE NEWSWIRE) -- Resmed (NYSE: RMD, ASX: RMD) today announced the election of Nicole Mowad-Nassar to its board of directors, effective August 15, 2025. The company als...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch